![IJMS | Free Full-Text | Free Light Chains κ and λ as New Biomarkers of Selected Diseases IJMS | Free Full-Text | Free Light Chains κ and λ as New Biomarkers of Selected Diseases](https://www.mdpi.com/ijms/ijms-24-09531/article_deploy/html/images/ijms-24-09531-g001.png)
IJMS | Free Full-Text | Free Light Chains κ and λ as New Biomarkers of Selected Diseases
Phenotyping Polyclonal Kappa and Lambda Light Chain Molecular Mass Distributions in Patient Serum Using Mass Spectrometry | Journal of Proteome Research
![Table 1 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar Table 1 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1444d9fcd1aa06934208ca29e69340f3ca084cbe/2-Table1-1.png)
Table 1 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar
![Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1444d9fcd1aa06934208ca29e69340f3ca084cbe/3-Table2-1.png)
Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar
![Full article: The cut-offs for kappa/lambda ratio in bone marrow immunohistochemistry for the diagnosis of multiple myeloma Full article: The cut-offs for kappa/lambda ratio in bone marrow immunohistochemistry for the diagnosis of multiple myeloma](https://www.tandfonline.com/cms/asset/f3ebe493-0329-459c-9c26-df65d8115f43/yhem_a_1802929_f0001_oc.jpg)
Full article: The cut-offs for kappa/lambda ratio in bone marrow immunohistochemistry for the diagnosis of multiple myeloma
![Demystifying Serum Free Light Chains – a guide for primary care - Manchester University NHS Foundation Trust Demystifying Serum Free Light Chains – a guide for primary care - Manchester University NHS Foundation Trust](https://mft.nhs.uk/app/uploads/2023/01/Myeloma-diagnostic-tool.png)
Demystifying Serum Free Light Chains – a guide for primary care - Manchester University NHS Foundation Trust
![Table 3 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar Table 3 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1444d9fcd1aa06934208ca29e69340f3ca084cbe/3-Table3-1.png)
Table 3 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar
Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels | Haematologica
![Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis – a pilot study | BMC Cancer | Full Text Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis – a pilot study | BMC Cancer | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2F1471-2407-7-185/MediaObjects/12885_2007_Article_835_Fig1_HTML.jpg)
Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis – a pilot study | BMC Cancer | Full Text
![Subset of Kappa and Lambda Germline Sequences Result in Light Chains with a Higher Molecular Mass Phenotype | Journal of Proteome Research Subset of Kappa and Lambda Germline Sequences Result in Light Chains with a Higher Molecular Mass Phenotype | Journal of Proteome Research](https://pubs.acs.org/cms/10.1021/acs.jproteome.5b00711/asset/images/medium/pr-2015-00711n_0008.gif)